Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05320159 · ClinicalTrials.gov registry record
Treatment Effectiveness Among Psoriasis Patients Treated With Cosentyx (Secukinumab)
A clinical trial, sponsored by Novartis Pharmaceuticals.
- Completed
- Registry status
- 17,743
- Enrollment target
NCT05320159: Completed study, sponsored by Novartis Pharmaceuticals.
NCT05320159 is a clinical trial that has completed, run by Novartis Pharmaceuticals. The registered enrollment target is 17,743 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05320159 has completed, sponsored by Novartis Pharmaceuticals.
- COMPLETED
- Registry status
- 17,743 participants
- Enrollment target
Study Summary
This was a retrospective cohort study utilizing data from Modernizing Medicine Data Services' (MMDS) electronic medical records (EMR)-based dermatology database to evaluate secukinumab patient characteristics, treatment patterns, and outcomes.
Primary Outcome
Patient reported satisfaction with treatment effectiveness was captured on a 5-point scale - "I believe this treatment is effective in clearing my skin of psoriasis." (1 = strongly agree, 2 = somewhat agree, 3 = Neither agree nor disagree, 4 = Somewhat disagree, 5 = Strongly disagree; n, %) in the EMR data system. For this analysis, the responses were classified into three groups: 1. Satisfied with treatment effectiveness (1 = strongly agree, 2 = somewhat agree) 2. Dissatisfied with treatment
Interventions
- DRUG Secukinumab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 17,743 participants |
| Start Date | 2021-02-03 |
| Est. Completion | 2021-03-31 |
What the finished NCT05320159 record still lists
NCT05320159 is an observational study that tracks outcomes without assigning an intervention. Its 17,743 participants enrollment target places it among the larger protocols in the corpus.
The record links to 0 conditions, and to 1 intervention - of which Secukinumab is the first listed.
NCT05320159 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT05320159 about?
NCT05320159 is a clinical study titled "Treatment Effectiveness Among Psoriasis Patients Treated With Cosentyx (Secukinumab)". This was a retrospective cohort study utilizing data from Modernizing Medicine Data Services' (MMDS) electronic medical records (EMR)-based dermatology database to evaluate secukinumab patient characteristics, treatment patterns, and outcomes.
What is the current status of trial NCT05320159?
This trial is currently completed. The enrollment target is 17,743 participants. The study started on 2021-02-03. Estimated completion is 2021-03-31.
What interventions are being tested in trial NCT05320159?
The interventions under investigation include: Secukinumab (DRUG).
Who is sponsoring clinical trial NCT05320159?
This trial is sponsored by Novartis Pharmaceuticals, which has 1,375 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT07108660 · 17,800 participants · NA
Machine Learning Prediction of Possible Central Line Associated Blood Stream Infections and Rate of Reduction
- NCT07290361 · 17,587 participants · NA
Stratified Targeted Engagement From Primary Care to Physical Therapy (STEPPT)
- NCT06272110 · 17,500 participants
Promoting Equitable Access to Language Services in Health and Human Services
- NCT04110522 · 18,000 participants · NA
Psoriatic Arthritis D2P Screening
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI